PubMed:8508358 JSONTXT

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":198,"end":223},"obj":"protein"},{"id":"T2","span":{"begin":606,"end":627},"obj":"protein"},{"id":"T3","span":{"begin":850,"end":855},"obj":"protein"},{"id":"T4","span":{"begin":1066,"end":1071},"obj":"protein"},{"id":"T5","span":{"begin":1255,"end":1280},"obj":"protein"},{"id":"T6","span":{"begin":1352,"end":1377},"obj":"protein"}],"text":"Proliferation index as a prognostic marker in breast cancer.\nBACKGROUND: The proliferative activity of tumors has been extensively investigated with different approaches, among which the use of the monoclonal antibody Ki-67 represents an easy and reliable means of assessing cell proliferation. In this study, the proliferative activity of 129 primary breast cancers was investigated, and the results were related to prognosis.\nMETHODS: Tumor samples, obtained from 129 patients who underwent surgery between January 1987 and December 1988, were processed for staining by an immunohistochemical procedure (avidin-biotin complex). The median time of observation was 42 months (range, 31-55 months). Life-table analysis (Mantel-Cox) was used to assess the probability of disease-free survival (DFS) and overall survival (OS).\nRESULTS: Tumors with high Ki-67 proliferation indices (\u003e 20%) were associated with a higher 4-year probability of relapse of disease (55.3% versus 79.1%; P = 0.003) and death (71% versus 95.6%; P = 0.00005) when compared with tumors with low Ki-67 values. In addition, this proliferative parameter maintained its prognostic significance when the patients were stratified according to lymph node involvement, menopausal status, and nuclear estrogen receptor content.\nCONCLUSIONS: Tumor proliferative activity as evaluated by the monoclonal antibody Ki-67 seems to be an effective indicator of prognosis in breast cancer for DFS and OS."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"S2","span":{"begin":61,"end":72},"obj":"Sentence"},{"id":"S3","span":{"begin":73,"end":294},"obj":"Sentence"},{"id":"S4","span":{"begin":295,"end":427},"obj":"Sentence"},{"id":"S5","span":{"begin":428,"end":436},"obj":"Sentence"},{"id":"S6","span":{"begin":437,"end":629},"obj":"Sentence"},{"id":"S7","span":{"begin":630,"end":697},"obj":"Sentence"},{"id":"S8","span":{"begin":698,"end":823},"obj":"Sentence"},{"id":"S9","span":{"begin":824,"end":832},"obj":"Sentence"},{"id":"S10","span":{"begin":833,"end":1079},"obj":"Sentence"},{"id":"S11","span":{"begin":1080,"end":1289},"obj":"Sentence"},{"id":"S12","span":{"begin":1290,"end":1302},"obj":"Sentence"},{"id":"S13","span":{"begin":1303,"end":1458},"obj":"Sentence"}],"text":"Proliferation index as a prognostic marker in breast cancer.\nBACKGROUND: The proliferative activity of tumors has been extensively investigated with different approaches, among which the use of the monoclonal antibody Ki-67 represents an easy and reliable means of assessing cell proliferation. In this study, the proliferative activity of 129 primary breast cancers was investigated, and the results were related to prognosis.\nMETHODS: Tumor samples, obtained from 129 patients who underwent surgery between January 1987 and December 1988, were processed for staining by an immunohistochemical procedure (avidin-biotin complex). The median time of observation was 42 months (range, 31-55 months). Life-table analysis (Mantel-Cox) was used to assess the probability of disease-free survival (DFS) and overall survival (OS).\nRESULTS: Tumors with high Ki-67 proliferation indices (\u003e 20%) were associated with a higher 4-year probability of relapse of disease (55.3% versus 79.1%; P = 0.003) and death (71% versus 95.6%; P = 0.00005) when compared with tumors with low Ki-67 values. In addition, this proliferative parameter maintained its prognostic significance when the patients were stratified according to lymph node involvement, menopausal status, and nuclear estrogen receptor content.\nCONCLUSIONS: Tumor proliferative activity as evaluated by the monoclonal antibody Ki-67 seems to be an effective indicator of prognosis in breast cancer for DFS and OS."}

{"project":"genia-medco-coref","denotations":[{"id":"C1","span":{"begin":73,"end":109},"obj":"NP"},{"id":"C2","span":{"begin":149,"end":169},"obj":"NP"},{"id":"C3","span":{"begin":177,"end":182},"obj":"NP"},{"id":"C4","span":{"begin":630,"end":660},"obj":"NP"},{"id":"C5","span":{"begin":665,"end":696},"obj":"NP"},{"id":"C6","span":{"begin":769,"end":796},"obj":"NP"},{"id":"C7","span":{"begin":801,"end":822},"obj":"NP"},{"id":"C8","span":{"begin":1093,"end":1121},"obj":"NP"},{"id":"C9","span":{"begin":1133,"end":1136},"obj":"NP"},{"id":"C10","span":{"begin":1303,"end":1331},"obj":"NP"},{"id":"C11","span":{"begin":1447,"end":1450},"obj":"NP"},{"id":"C12","span":{"begin":1455,"end":1457},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-relat","subj":"C3","obj":"C2"},{"id":"R2","pred":"coref-ident","subj":"C5","obj":"C4"},{"id":"R3","pred":"coref-pron","subj":"C9","obj":"C8"},{"id":"R4","pred":"coref-ident","subj":"C10","obj":"C1"},{"id":"R5","pred":"coref-ident","subj":"C11","obj":"C6"},{"id":"R6","pred":"coref-ident","subj":"C12","obj":"C7"}],"text":"Proliferation index as a prognostic marker in breast cancer.\nBACKGROUND: The proliferative activity of tumors has been extensively investigated with different approaches, among which the use of the monoclonal antibody Ki-67 represents an easy and reliable means of assessing cell proliferation. In this study, the proliferative activity of 129 primary breast cancers was investigated, and the results were related to prognosis.\nMETHODS: Tumor samples, obtained from 129 patients who underwent surgery between January 1987 and December 1988, were processed for staining by an immunohistochemical procedure (avidin-biotin complex). The median time of observation was 42 months (range, 31-55 months). Life-table analysis (Mantel-Cox) was used to assess the probability of disease-free survival (DFS) and overall survival (OS).\nRESULTS: Tumors with high Ki-67 proliferation indices (\u003e 20%) were associated with a higher 4-year probability of relapse of disease (55.3% versus 79.1%; P = 0.003) and death (71% versus 95.6%; P = 0.00005) when compared with tumors with low Ki-67 values. In addition, this proliferative parameter maintained its prognostic significance when the patients were stratified according to lymph node involvement, menopausal status, and nuclear estrogen receptor content.\nCONCLUSIONS: Tumor proliferative activity as evaluated by the monoclonal antibody Ki-67 seems to be an effective indicator of prognosis in breast cancer for DFS and OS."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":0,"end":19},"obj":"other_name"},{"id":"T2","span":{"begin":25,"end":42},"obj":"other_name"},{"id":"T3","span":{"begin":46,"end":59},"obj":"other_name"},{"id":"T4","span":{"begin":103,"end":109},"obj":"other_name"},{"id":"T5","span":{"begin":198,"end":223},"obj":"protein_family_or_group"},{"id":"T6","span":{"begin":344,"end":366},"obj":"other_name"},{"id":"T7","span":{"begin":437,"end":450},"obj":"tissue"},{"id":"T8","span":{"begin":470,"end":478},"obj":"multi_cell"},{"id":"T9","span":{"begin":575,"end":604},"obj":"other_name"},{"id":"T10","span":{"begin":606,"end":627},"obj":"protein_complex"},{"id":"T11","span":{"begin":769,"end":790},"obj":"other_name"},{"id":"T12","span":{"begin":833,"end":839},"obj":"tissue"},{"id":"T13","span":{"begin":845,"end":849},"obj":"other_name"},{"id":"T14","span":{"begin":850,"end":855},"obj":"protein_molecule"},{"id":"T15","span":{"begin":1066,"end":1071},"obj":"protein_molecule"},{"id":"T16","span":{"begin":1170,"end":1178},"obj":"multi_cell"},{"id":"T17","span":{"begin":1208,"end":1230},"obj":"other_name"},{"id":"T18","span":{"begin":1232,"end":1249},"obj":"other_name"},{"id":"T19","span":{"begin":1255,"end":1280},"obj":"protein_family_or_group"},{"id":"T20","span":{"begin":1303,"end":1331},"obj":"other_name"},{"id":"T21","span":{"begin":1352,"end":1377},"obj":"protein_molecule"}],"text":"Proliferation index as a prognostic marker in breast cancer.\nBACKGROUND: The proliferative activity of tumors has been extensively investigated with different approaches, among which the use of the monoclonal antibody Ki-67 represents an easy and reliable means of assessing cell proliferation. In this study, the proliferative activity of 129 primary breast cancers was investigated, and the results were related to prognosis.\nMETHODS: Tumor samples, obtained from 129 patients who underwent surgery between January 1987 and December 1988, were processed for staining by an immunohistochemical procedure (avidin-biotin complex). The median time of observation was 42 months (range, 31-55 months). Life-table analysis (Mantel-Cox) was used to assess the probability of disease-free survival (DFS) and overall survival (OS).\nRESULTS: Tumors with high Ki-67 proliferation indices (\u003e 20%) were associated with a higher 4-year probability of relapse of disease (55.3% versus 79.1%; P = 0.003) and death (71% versus 95.6%; P = 0.00005) when compared with tumors with low Ki-67 values. In addition, this proliferative parameter maintained its prognostic significance when the patients were stratified according to lymph node involvement, menopausal status, and nuclear estrogen receptor content.\nCONCLUSIONS: Tumor proliferative activity as evaluated by the monoclonal antibody Ki-67 seems to be an effective indicator of prognosis in breast cancer for DFS and OS."}